Summary

for people ages 18-99 (full criteria)
at La Jolla, California and other locations
study started
estimated completion:

Description

Summary

This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.

Official Title

Uptravi® (SelexiPag): tHe usErs dRug rEgistry

Keywords

Pulmonary Arterial Hypertension Hypertension Familial Primary Pulmonary Hypertension Selexipag

Eligibility

You can join if…

Open to people ages 18-99

  • Signed patient informed consent form (ICF).
  • Patients with PAH who either initiate Uptravi at the time of enrollment or have been receiving treatment with Uptravi and have a documented titration regimen (defined as all documented dose changes including, but not limited to: starting dose and highest tolerated dose).
  • Patients ≥ 18 years of age at time of Uptravi initiation.

You CAN'T join if...

  • Patients previously exposed to Uptravi treatment during a clinical trial.
  • Patients that previously discontinued Uptravi for any reason, prior to study enrollment (discontinuation defined as an interruption of therapy greater than or equal to 30 days).
  • Patients enrolled in a blinded clinical trial or in a clinical trial involving an unapproved drug.

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92093 United States
  • LA Biomed Research Inst at Harbor UCLA Medical Center accepting new patients
    Torrance California 90502 United States
  • University of Southern California accepting new patients
    Los Angeles California 90033 United States
  • VA Greater Los Angeles Healthcare Center accepting new patients
    Los Angeles California 90073 United States
  • Santa Barbara Cottage Hospital accepting new patients
    Santa Barbara California 93105 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Actelion
ID
NCT03278002
Study Type
Observational [Patient Registry]
Last Updated
April 17, 2018